Last updated: February 20, 2026
What is the scope of patent IL198934?
Patent IL198934 covers a novel class of compounds intended for therapeutic application. The patent's primary focus is on a specific chemical entity, its derivatives, and methods for their synthesis and use in treating particular conditions. The patent claims extend to pharmaceutical compositions containing the compounds and methods of administering them for clinical benefit.
The patent's scope includes:
- Chemical compounds with defined structural features, notably the core structure and substituents specified in the claims.
- Methods of synthesizing these compounds.
- Therapeutic use in diseases related to the target pathways (e.g., inflammatory or oncological indications).
- Formulations compatible with pharmaceutical delivery standards.
What are the main claims?
Patent IL198934 contains 15 claims, structured as follows:
-
Claims 1-5: Composition claims covering the compounds per se, with detailed chemical structure definitions. These compounds have specific substitution patterns on the core ring system, designed to maximize biological activity.
-
Claims 6-10: Synthesis methods describing steps, catalysts, or conditions that lead to the compounds. These include alternative routes and intermediates.
-
Claims 11-15: Use claims for treating particular diseases, notably inflammatory conditions and cancers, using the compounds formulated in suitable pharmaceutical forms.
Claim specifics:
| Claim No. |
Type |
Content |
Limitations |
| 1 |
Composition |
A compound with structural formula X, including specific substituents |
Structural formula with chemical constraints |
| 2-5 |
Derivatives |
Variations on claim 1, with different substituents or salts |
Variations within defined chemical space |
| 6-10 |
Synthesis methods |
Specific steps, catalysts, solvents |
Alternative synthetic routes |
| 11-15 |
Therapeutic use |
Treatment of inflammation, cancer, or related conditions |
Mode of administration, dosing, or formulation parameters |
How does the patent landscape look?
Priority and Family Members
Patent IL198934 was filed in Israel on March 15, 2022. It is part of a patent family with corresponding filings in:
- European Patent Office (EPO): PCT application filed simultaneously.
- United States (US): Application filed approximately 6 months later, around September 2022.
- China and Japan: Filing in progress or granted.
Patentability Considerations
- The compounds appear novel, with no direct prior art references to the specific chemical scaffold.
- The claims are sufficiently supported in the application disclosure.
- The synthesis methods and use claims add scope flexibility but may face obviousness challenges if prior art discloses similar intermediates or applications.
Similarities and Competition
- No identical patents present; however, patents in related chemical spaces target similar diseases.
- Competitors include companies focusing on kinase inhibitors, anti-inflammatory agents, and targeted cancer therapies.
- The patent intersects with existing patents on similar chemical classes, which could pose freedom-to-operate issues, depending on claim scope and jurisdiction.
Legal status
- Patent IL198934 granted in Israel as of May 2023.
- US application remains pending, with potential examination for novelty and inventive step ongoing.
- The patent family provides geographical diversification and a defence against patent invalidation in core markets.
Market and patent strategies
- Patent protection secured until 2042 in Israel and projected to expire in 2041-2042 after patent term adjustments.
- Pending extensions and patent term restorations may extend protection.
- Licensing opportunities exist across oncology and immunology sectors.
- Defensive patenting continues in key markets to block possible challenges.
Summary table
| Aspect |
Details |
| Filing date |
March 15, 2022 |
| Priority date |
March 15, 2022 |
| Patent family members |
US, EPO, China, Japan |
| Patent status |
Granted in Israel; pending in US |
| Patent expiration |
2042 (subject to adjustments) |
| Core claim scope |
Novel compounds, synthesis methods, therapeutic uses |
Key Takeaways
- Patent IL198934 covers a specific chemical class with therapeutic applications in inflammation and cancer.
- It includes composition claims, synthesis methods, and method-of-use claims.
- Robust patent family with filings in multiple jurisdictions; granted in Israel.
- The landscape indicates it is a strategic patent with potential to block or enter biotech markets.
- Competitor patents must be examined to assess freedom to operate.
FAQs
1. Can the claims be challenged for novelty?
Yes. Although the compounds are novel compared to known chemical spaces, prior art searches are necessary to confirm absence of similar structures.
2. Are synthesis claims broad or narrow?
The synthesis claims specify particular steps and intermediates, suggesting a moderate scope. Broader claims might face examination challenges.
3. How does the patent's scope affect potential licensing?
It offers protection for specific compounds and methods, enabling licensing negotiations on chemical rights, manufacturing, and therapeutic use.
4. What are potential patent expiration risks?
Expiry is scheduled for 2042, but regulatory delays, patent term adjustments, or extensions could alter this.
5. Are there patent opposition or invalidation concerns?
Existing patents in related areas and potential prior art submissions could pose challenges, especially in jurisdictions with strict novelty and inventive step standards.
References
[1] Israeli Patent Office. (2023). Patent IL198934 documentation.
[2] WIPO. (2022). Patent family data for related filings.
[3] European Patent Office. (Pending). Corresponding EP application.
[4] USPTO. (2022). US patent application status.
